Community Investing Ideas

Global Weekly Picks

AU$196.78
FV
41.9% undervalued intrinsic discount
17.32%
Revenue growth p.a.
1.1k
users have viewed this narrative
16users have liked this narrative
4users have commented on this narrative
21users have followed this narrative
US$18.17
FV
55.2% overvalued intrinsic discount
1.28%
Revenue growth p.a.
378
users have viewed this narrative
3users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
US$408.64
FV
40.2% undervalued intrinsic discount
20.00%
Revenue growth p.a.
673
users have viewed this narrative
12users have liked this narrative
2users have commented on this narrative
22users have followed this narrative
US$1.2
76.3% undervalued intrinsic discount
Profit Margin
13.5%
Future PE
35.64x
Price in 2031
US$2.15
₹135.87
156.3% overvalued intrinsic discount
Salman2415's Fair Value
Revenue
23% p.a.
Profit Margin
5%
Future PE
28x
Price in 2031
₹239.45
US$110.76
11.8% undervalued intrinsic discount
Roaming446's Fair Value
Revenue
14% p.a.
Profit Margin
24.3%
Future PE
32.52x
Price in 2031
US$169.67
TLX logo
Telix Pharmaceuticals

TLX... a Market's Overreaction or a Falling Knife?

So just for context to any investors happening upon this narrative... What does Telix actually do?Read more

View narrative
33
users have viewed this narrative
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AU$18
45.2% undervalued intrinsic discount
Vallix's Fair Value
Profit Margin
13%
Future PE
27.9x
Price in 2029
AU$22.19
US$362.4
30.3% undervalued intrinsic discount
Vestra's Fair Value
Profit Margin
7.55%
Future PE
19.08x
Price in 2031
US$553.22